INTRODUCTION
SSc, an autoimmune disease with one of the worst prognosis, is characterised by fibrosis, vasculopathy and immune dysregulation, leading to multiple organ damage. It is a relatively rare disease with prevalence estimates of 21 per million (Japanese) to 315 per million (Africans). Ethnicity has a significant impact on the epidemiology, clinical manifestations, survival, autoantibody frequencies and genetic factors in SSc 1 . By understanding the variation of these factors with ethnicity, appropriate treatment, monitoring and prognostication may be possible.
In multi-ethnic Western cohorts, African-Americans were found to have a higher disease prevalence 2 and more severe disease than their Caucasian counterparts. African-Americans developed SSc at an earlier age, and were more likely to have DcSSc, digital ulcers, digital pitting, impaired lung function, and anti-U1RNP, and anti-Ro antibodies 3 . In a small comparative study of Chinese versus Caucasian SSc patients in Canada, Chinese patients had less frequent digital ulceration, joint and GI involvement, and an absence of renal crisis. However, more Chinese patients had myositis and were positive for anti-Scl-70, anti-Ro and anti-U1RNP 4 . In a small Singaporean Asian Proceedings of Singapore Healthcare  Volume 22  Number 1  2013 cohort (n=68), we found that the frequencies of anti-centromere (23.5%) and anti-ribonucleic acid (anti-RNA) polymerase III (4.4%) antibodies were lower compared to historical cohorts of Caucasians from the United States (US) and United Kingdom (UK) (30-32% and 13-32%, respectively). Conversely, anti-Scl-70 (30.9%), anti-U1RNP (23.9%) and anti-Ro (27.3%) were higher in Asians compared to Caucasians (13-21%, 5-7%, and 3-4%, respectively) 1, 5 .
It is thus important to study the disease in Asian patients so that disease management and treatment can be more appropriately targeted. Singapore is a multi-ethnic population of about 5.1 million people (2010 population census) 6 , comprising mainly Chinese (74%), Malays (13%) and Indians (9%), and represents a unique population to investigate disease manifestations among Asian patients.
In 2008, the SSc Workgroup was initiated with the goals of (i) synergising on the expertise distributed among the Rheumatology Centres in Singapore, (ii) fostering collaboration to achieve critical mass in numbers and complexity of patients, and thus (iii) permitting advancement of SSc care and research. In this study, we aimed to characterise the disease and autoantibody profile of Asian patients with SSc.
METHODS
Started in 2008, the Singapore SSc database consists of prevalent and incident cases from four institutions (National University Hospital, Singapore General Hospital, Tan Tock Seng Hospital, and Khoo Teck Puat Hospital). Data on demographics, disease manifestations, autoantibody profile and treatment were recorded annually according to a standardised protocol.
The study was approved by the respective institution's centralised institutional review board and conducted according to the Declaration of Helsinki.
Study Population
SSc patients fulfilled the ACR classification criteria 7 or the criteria for VEDOSS 8 which includes SScspecific nailfold capillaroscopic (NFC) abnormalities and autoantibodies. Patients were determined to have LcSSc or DcSSc according to LeRoy criteria 7 . SSc sine scleroderma was defined by the absence of skin sclerosis in the presence of typical visceral involvement. Overlap syndrome was defined as SSc occurring with one or more connective tissue diseases, namely systemic lupus erythematosus (SLE), rheumatoid arthritis (RA) and polymyositis/ dermatomyositis (PM/DM) fulfilling established classification criteria.
Disease Manifestations
SSc manifestations included joint pain, joint contracture, Raynaud's phenomenon, digital tip pitting scars, digital ulcers, digital gangrene, myopathy and myositis (fulfilling two and three of Bohan and Peter criteria, respectively), GI (presence of symptoms/investigations confirming gastroesophageal reflux, hypomotility, bacterial overgrowth, malabsorption, gastric antral vascular ectasia or faecal incontinence), ILD (fibrosis and/or ground glass opacities on pulmonary high resolution computed tomography (HRCT), a restrictive pattern on pulmonary function test or fibrosis on chest X-ray), PAH (pulmonary arterial systolic pressure >40 mmHg on echocardiography) and renal crisis (acute renal failure associated with the abrupt onset of moderate-to-severe hypertension in the absence of other causes of renal failure). Skin sclerosis was evaluated using the modified Rodnan skin score (mRSS). The autoantibody profile and treatment were also recorded.
Statistical Analysis
Data were analysed using descriptive statistics. Categorical variables were analysed using chisquared or Fisher's exact tests, as appropriate. Continuous variables were analysed using the t-test or non-parametric Mann Whitney U test as appropriate. P values less than 0.05 were considered to be statistically significant. Analyses were performed using Excel 2010 and SPSS version 11.5.
RESULTS

Demographics
As of October 2012, 200 patients (Chinese 78%, Malays 10.5%, Indians 6%, other ethnicity 5.5%) who fulfilled the ACR (n=176, 88%) or VEDOSS (n=24, 12%) criteria were recruited. Patients were subtyped into LcSSc (n=63, 32%) or DcSSc (n=74, 37.6%), SSc-overlap syndromes (n=54, 27.4%) and sine scleroderma (n=6, 3%). Of patients with SScoverlap syndrome, 34 (63%) had an overlap with LcSSc and 18 (33.3%) had an overlap with DcSSc. The corresponding overlapping connective tissue Proceedings of Singapore Healthcare  Volume 22  Number 1  2013 diseases were RA (n=20), SLE (n=23) and PM/DM (n=18). Mean age at diagnosis was 46+14.9 years with no statistically significant difference between DcSSc (47.1+14 years) or LcSSc (48.8+15.3 years) subtypes. Patients with overlap syndromes were diagnosed at a younger age (42.4+15.1 years). Overall, females were more affected (sex ratio female/male 6:1), although the relative proportion of males was higher in patients with DcSSc (sex ratio female/male 4:1) than LcSSc (sex ratio female/ male 7:1). Of 137 patients in whom employment status was known, 53.3% participated in a paid job or were full-time students, 13.9% were unemployed due to their medical condition, and the remaining 32.8% were homemakers (n=25), retired (n=14) or unemployed due to non-medical reasons (n=6).
Disease Characteristics (Table 1)
The predominant disease manifestations were Raynaud's phenomenon (80.5%), GI involvement (62.5%; upper and lower GI involvement occurring in 59.5% and 22.5%, respectively), joint pain (58%) and ILD (n=99, 51.8%, diagnosed by pulmonary HRCT, pulmonary function test or chest radiograph). Of 168 patients who had an echocardiography, 39 (23.2%) patients were suspected to have PAH (systolic pulmonary arterial pressure, sPAP >40mmHg), subsequently confirmed in 10 of 12 patients by right heart catheterisation. The remaining two patients may have early/borderline PAH (mean PAP 21 and 22 mmHg, respectively). Patients with PAH on echocardiography had a mean sPAP of 55.0+19.7 mmHg (data not shown). 
Autoantibodies (Table 2)
ANA was detected in 78.7% of patients. The most prevalent SSc-associated autoantibodies were anti-Scl-70 (35%), anti-RNP (29.2%) and anti-Ro60 (20.7%). Anti-centromere antibodies were infrequently detected (12.1%). The presence of anti-centromere antibodies was associated with LcSSc, and anti-Scl-70 was associated with DcSSc.
Of the non-SSc-associated autoantibodies, rheumatoid factor was frequently detected (34.4%), although anti-cyclic citrullinated peptide was infrequent (7.8%).
Treatment
Treatment (ever-treated) included corticosteroids (80.7%), for peripheral vasculopathy (61.4%, most frequently calcium channel blockers, angiotensin converting enzyme [ACE]-inhibitors and ACEreceptor blocker), GI (68%, most frequently proton pump inhibitors, H2-antagonist and pro-motility agents), PAH (11.2%, most frequently anticoagulation and phosphodiesterase-5 inhibitor) and immunosuppression (62.9%, most frequently methotrexate, cyclophosphamide and azathioprine).
DISCUSSION
We described the disease characteristics of SSc in a predominantly Chinese (78%) Asian cohort. Our study represents one of the largest Asian cohorts of SSc patients. Other Asian cohorts originate from Thailand (n=66) 9 , Malaysia (n=61 and n=23) 10, 11 , India (n=100) 12 and Japan (n=357) 13 . Our findings confirm the ethnic influence on disease manifestations and autoantibodies in SSc.
Demographics
Eighty-eight percent of our cohort fulfilled the ACR criteria, with the remaining patients (12%) fulfilling the proposed criteria for VEDOSS 8 . This is similar to the European League Against Rheumatism Scleroderma Trials and Research (EUSTAR) cohort 14 in which 84% fulfilled the ACR criteria. The widely used ACR criteria lacks sensitivity and typically only identifies 70% of SSc patients and 34% of patients with LcSSc 7 . The sensitivity can be increased from 34% to 83% by including the evaluation of the microcirculation using NFC 15 and SSc-specific autoantibodies which is included in the VEDOSS criteria. The importance in identifying such patients who do not fulfill the ACR criteria is to screen for organ involvement in SSc. In particular, ILD and PAH are major causes of death in SSc 16 , and may be relatively asymptomatic in the early stages. The three major components of the VEDOSS criteria are the presence of Raynaud's phenomenon, SScspecific autoantibodies and typical scleroderma pattern on NFC. Compared to the EUSTAR cohort, the prevalence of Raynaud's phenomenon (80.5% vs. 96.3% EUSTAR) and positive ANA (78.7% vs. 93.4% EUSTAR) is lower in our cohort, increasing the value of performing NFC examination in our cohort.
Compared to a large multi-ethnic US cohort, the mean age at diagnosis of our patients (46.0 years) was similar to the African-Americans (43.8 years) but younger than the Caucasian-Americans (55.5 years) 2 . Interestingly, in a systematic review of disease characteristics comparing studies from Europe, Asia (Japan, India and Iraq) and North America, mean age at onset was highest in North America (52 years), followed by Europe (48 years) and Asia (34 years) 17 , suggesting a geo-ethnic influence on disease onset.
A significant proportion (14%) of our patients were unemployed due to their medical condition, illustrating the high burden of disease affecting patients at the prime of their working lives. In a US cohort 18 , work disability in SSc patients was high. Presence of a high fatigue score, lower lung function parameter and non-Caucasian ethnicity predicted work disability.
Disease Characteristics
Unlike the Caucasian cohorts 2, 14 in which the majority of patients (59%-73%) had LcSSc, our cohort had slightly more patients with DcSSc (38%) than LcSSc (32%), and 27% of patients with SSc-overlap syndromes.
The most frequent disease manifestations were Raynaud's phenomenon, GI involvement, joint pain and ILD. In our cohort, the frequency of Raynaud's phenomenon was comparatively lower than other Western cohorts that typically report frequencies of more than 95%. This is likely due to the warm climate in Singapore.
The frequencies of GI involvement, joint contractures, cardiac, ILD and PAH by echocardiography were similar to the EUSTAR cohort 14 . Renal crisis was rare, similar to the EUSTAR cohort (2%), but lower than most other Western cohorts that report a prevalence of 6-9% 17 . The discrepancy may be due to a relatively shorter duration of follow-up of the EUSTAR cohort started in 2004. ACE-inhibitors (introduced in the 1980's) is thought to contribute to the increased five-year cumulative survival for patients with renal crisis from less than 10% to 65% 16 . Alternatively, there may be an ethnic difference in the predilection to renal crisis. Anti-RNA polymerase III, associated with high risk for renal crisis, was found to be uncommon (4%) in our cohort 5 compared to Western cohorts (13-32%) 1 .
The frequency of ILD in our study was similar to the EUSTAR cohort. When ILD was diagnosed by HRCT, frequencies were as high as 59% and 52%, respectively. Corresponding frequencies when diagnosed by chest X-ray were 23% and 40%, respectively. In a systematic review, pulmonary involvement was highest in Asia (60%), followed by Europe (42%) and North America (30%). However, the definition of the nature of pulmonary involvement in that review was not stated. Prevalence of PAH by echocardiography in our cohort (24%) was similar to the EUSTAR cohort (21%). However, patients in our cohort had more severe PAH (mean sPAP 55.0+19.7 mmHg) than the EUSTAR cohort (mean sPAP 46.8+15.5 mmHg) 14 .
Analysis of data by SSc subtypes showed that DcSSc was associated with increased risk for joint contractures and digital ulcers possibly due to the overlying tight skin and recurrent trauma from the joint contractures. In a large UK registry of SSc patients with a history of digital ulcers, the early occurrence and high frequency of digital ulcers were especially seen in patients with DcSSc and/ or anti-Scl-70 antibodies 19 . Our patients with DcSSc were also more likely to have proximal myopathy and raised muscle enzymes. of Chinese SSc patients in a Canadian cohort and a Singapore study validating a new line immunoassay for the detection of SSc-associated autoantibodies 4, 5 . The clinical significance of the above findings will need to be further investigated.
Autoantibodies
As the routinely available SSc-specific autoantibodies (anti-Scl-70 and anti-centromere) were only present in 47% of patients, further evaluation using a new SSc line immunoassay may be useful for the early diagnosis of patients, with a reported additional diagnostic yield of 15% in our cohort 5 .
Treatment
The use of corticosteroids was high (81%) compared to the EUSTAR cohort (45%). Data was not available for the duration or dosage of corticosteroids used, or the reasons for prescription. Our cohort had a high proportion of patients with SSc-overlap and ILD, which may have necessitated the more frequent use of corticosteroids. In SSc, the use of corticosteroids has been associated with an increased risk of renal crisis. This was not seen in our cohort despite the high usage of corticosteroids. Other risk factors, such as ethnicity or autoantibodies, are therefore likely to play a greater contributory role to the risk of renal crisis. The use of other treatments, including immunosuppression, was comparable to the EUSTAR cohort.
In summary, our findings add to the literature and confirm the ethnic influence on disease manifestations and autoantibodies in SSc. Compared to Caucasian patients, our predominantly Chinese Asian SSc patients were diagnosed at an earlier age, more patients with DcSSc, more severe PAH, less frequent Raynaud's phenomenon, and an autoantibody profile characterised by anti-Scl70, anti-RNP and anti-Ro60, and infrequently anti-centromere.
